on august 28, at the 2025 china international big data industry expo, the national data administration launched a pilot work for the construction of high-quality data sets, accelerated the pace of high-quality data set construction, and promoted the implementation of the "artificial intelligence +" action. among the first batch of high-quality data sets released to be piloted and trial, jinfeng laboratory was successfully selected for the "standardized high-quality data sets for disease pathology diagnosis".

since its establishment, jinfeng laboratory has focused on the core tasks of "next generation diagnosis of major diseases", accelerated the integration and innovation of pathological diagnosis and artificial intelligence technology, and promoted the iterative upgrade of "experienced medical treatment" to "intelligent disease calculation". in april this year, the laboratory started the construction of jinfeng smart pathology center and made the construction of standardized high-quality pathological sample data sets one of the important contents. the laboratory and 26 domestic medical institutions jointly launched the first "standardized pathology database plan for the tens of million-level pandemic diseases" and was authorized to build and operate the chongqing medical biological sample data resource library. the laboratory has initially established a standardized system for pathological samples and data throughout the life cycle, built a leading multimodal standardized data set for brain tumors and hematological diseases in china, and built the largest biological data storage and computing platform and pathological intelligent standardized computing platform in the west, providing strong support for the construction of standardized high-quality data sets.

as the first batch of pioneering units, jinfeng laboratory will accelerate the construction of standardized high-quality pathological sample data sets in accordance with the requirements of the national data bureau, in accordance with the requirements of the national data bureau, and accelerate the construction of standardized high-quality pathological sample data sets from the aspects of construction paths, mechanism innovation, quality assessment, standard verification, industry empowerment, etc., and widely cooperate with medical, scientific research and industrial institutions to continuously deepen data standardization and quality control mechanisms, promote cross-institutional and cross-regional data interconnection, explore compliant and reliable data sharing and innovative application paths, and make jinfeng contributions to the construction of high-quality data sets in my country's medical and health leaders.